Although CAR T-cell therapies have been found effective against certain difficult-to-treat malignancies, they are not devoid of safety concerns.

Cancer survivors want to see more access to screenings that they call "a game changer." It's called biomarker testing, which analyzes a patient's tissue, blood or other bodily fluids to help pinpoint ...

Among adults with relapsed or refractory indolent B-cell non-Hodgkin lymphoma, the phase 2 TRANSCEND FL trial met its primary ...

Bristol Myers Squibb (BMS) has reported that the multi-centre Phase II TRANSCEND FL trial assessing its cluster of ...

With another trial win, Bristol Myers Squibb is touting Breyanzi as the CD19-directed CAR-T therapy with positive readouts in the most cancer types. | With another trial win, Bristol Myers Squibb is ...

MSD has started a phase 3 trial of ROR1-directed zilovertamab vedotin (zilo-V) as a treatment for previously untreated ...

Co., Inc. (NYSE: MRK) has initiated a pivotal Phase 3 clinical trial, waveLINE-010, to evaluate the efficacy of its investigational drug zilovertamab vedotin in treating patients with previously ...

The Committee for Medicinal Products for Human Use (CHMP) has recommended that the CD19-directed CAR T cell therapy, which is already approved in the EU for certain lymphomas, be authorised to treat ...

Trusted resource of information on Cancer that includes articles, news, videos, animations, quizzes, calculators and drugs.

In an invited talk at the upcoming Tandem meetings, Dr. Megan Herr of Roswell Park Comprehensive Cancer Center will highlight the link between patients' physical function and CAR T outcomes; Dr.

Non-Hodgkin lymphoma is a cancer that affects lymphocytes, a type of white blood cells in the lymphatic system. They are generally classified according to the cancer's growth rate as high grade ...

an important new study found that ibrutinib shows some effectiveness in fighting a type of non-Hodgkin lymphoma called mantle cell lymphoma (MCL) though it doesn't increase the overall survival rate ...